胍法辛增强认知矫正联合社交技能训练治疗分裂型人格障碍
结果显示胍法辛组在MCCB推理与问题解决及UPSA总分上呈现显著的时间×药物交互作用,且两者联合干预耐受性良好、无脱落。
要点
- 胍法辛联合认知矫正与社交技能训练耐受性良好,无副作用或脱落。
- 胍法辛组在推理与问题解决及功能能力上较安慰剂组有显著改善。
- 认知矫正联合社交技能训练可能适合分裂型人格障碍患者。
核心结论
- 胍法辛增强认知矫正联合社交技能训练在推理与问题解决及功能能力上优于安慰剂,且可能改善社会认知。
- 认知矫正联合社交技能训练可能是分裂型人格障碍的合适干预,胍法辛是有前景的药物增强手段。
研究设计与样本
- 认知用MATRICS共识认知成套测验(MCCB)评估,社会认知用社会认知评估电影(MASC)评估,功能能力用加州大学圣地亚哥分校基于表现技能评估(UPSA)评估。
主要发现
- MCCB加工速度、言语学习和视觉学习及UPSA总分均观察到显著的治前与治后效应。
- MCCB推理与问题解决及UPSA总分观察到显著的时间×药物(胍法辛、安慰剂)交互作用。
- MASC心理化不足错误的时间×治疗交互作用接近显著。
- 胍法辛与认知矫正联合社交技能训练均耐受良好,无副作用或脱落。
临床怎么用
- 对分裂型人格障碍患者可考虑认知矫正联合社交技能训练作为心理社会干预。
- 胍法辛可作为增强该心理社会干预以改善推理与问题解决及功能能力的候选药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Impaired cognition is a hallmark of schizophrenia spectrum disorders, including schizotypal personality disorder, and it is the best predictor of functional outcome. Cognitive remediation therapy has demonstrated efficacy for improving cognition, augmenting other rehabilitation efforts in schizophrenia, and effecting gains in real-world functioning. Pharmacological augmentation of cognitive remediation has been attempted, but the effects of augmentation on combined therapies, such as cognitive remediation and social skills training, have not been studied. METHODS: Twenty-eight participants with schizotypal personality disorder enrolled in an 8-week, randomized, double-blind, placebo-controlled trial of guanfacine plus cognitive remediation and social skills training (15 guanfacine, 13 placebo). Cognition was assessed with the MATRICS (Measurement and Treatment Research to Improve Cognition in Schizophrenia) Consensus Cognitive Battery (MCCB), social cognition with the Movie for the Assessment of Social Cognition (MASC), and functional capacity with the University of California San Diego Performance-Based Skills Assessment (UPSA). RESULTS: A statistically significant pre- versus posttreatment effect was observed for MCCB speed of processing, verbal learning, and visual learning and UPSA total score. A significant time-by-medication (guanfacine, placebo) interaction was observed for MCCB reasoning and problem solving and UPSA total score; the time-by-treatment interaction approached significance for MASC hypomentalizing errors. CONCLUSIONS: Both guanfacine and cognitive remediation plus social skills training were well tolerated, with no side effects or dropouts. Participants treated with cognitive remediation, social skills training, and guanfacine demonstrated statistically significant improvements in reasoning and problem solving, as well as in functional capacity and possibly social cognition, compared with those treated with cognitive remediation, social skills training, and placebo. Cognitive remediation plus social skills training may be an appropriate intervention for individuals with schizotypal personality disorder, and guanfacine appears to be a promising pharmaceutical augmentation to this psychosocial intervention.
引用
- McClure MM, Graff F, Triebwasser J, et al. Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. Am J Psychiatry. 2019. PMID: 30654644. doi:10.1176/appi.ajp.2018.18030349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。